Skip to main content

Advertisement

SpringerLink
Log in

Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The role of dose-dense schedules in the neo-adjuvant treatment (NACT) of locally advanced cervical cancer (LACC) has been reported. This phase II study investigated activity of dose-dense paclitaxel/platinum before radical surgery (RS) in LACC patients.

Methods

The primary end-point was the rate of optimal pathological response (OPR: pathological complete/microscopic response). NACT (paclitaxel: 80 mg/m2) and carboplatin (AUC 2) were administered for 6 weeks. Overall response rate (ORR) to NACT was assessed by the RECIST criteria. Patients amenable to surgery were triaged to RS. The null hypothesis was that the OPR rate would improve from 30.0 to 45.0% (α error: 0.05, β error: 0.2). The regimen would be considered active if > 25 OPRs were found.

Results

36 patients were enrolled; 19 patients were stage IIB (52.8%) and 16 (44.4%) patients had pelvic lymph-node involvement at imaging. All patients completed neo-adjuvant chemotherapy; ORR was of 75.0%. RS was performed in 29 (93.5%) patients. Since the OPR was 16.1%, we evaluated the real chances to achieve the number of OPR required by the Simon design and decided to close the study. Grade 3/4 hematological toxicity occurred in 5 patients; surgical morbidity occurred in 14 patients. The 2-year PFS rate was 69.0%.

Conclusion

Dose-dense neo-adjuvant paclitaxel/carboplatin is feasible and safe in LACC patients; however, failure to achieve the primary end-point has to be recognized. Given the heterogeneity of the available studies, robust data from an adequately sized prospective study focused on more homogeneous series are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. McNeil C (1999) New standard of care for cervical cancer sets stage for next questions. J Natl Cancer Inst 91:500–501

    Article  PubMed  CAS  Google Scholar 

  2. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC) (2010) Reducing uncertainties about the effect of chemoradiotherapy for cervical cancer: individual patients data meta-analysis. Cochrane Database Syst Rev 1:CD008285

    Google Scholar 

  3. Shrivastava S, Mahantshetty U, Engineer R, Gynecologic Disease Management Group et al (2018) Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol 4(4):506–513

    Article  PubMed  PubMed Central  Google Scholar 

  4. Benedetti-Panici P, Greggi S, Colombo A et al (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20(1):179–188

    Article  PubMed  CAS  Google Scholar 

  5. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39:2470–2486

    Article  CAS  Google Scholar 

  6. Buda A, Fossati R, Colombo N et al (2005) Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, fosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 23(18):4137–4145

    Article  PubMed  CAS  Google Scholar 

  7. Lissoni AA, Colombo N, Pellegrino A et al (2009) A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol 20(4):660–665

    Article  PubMed  CAS  Google Scholar 

  8. He D, Duan C, Chen J et al (2015) The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer: a systematic review and meta analysis. Int J Clin Exp Med 8(9):14693–14700

    PubMed  PubMed Central  CAS  Google Scholar 

  9. Kokka F, Bryant A, Brockbank E et al (2015) Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 4:CD010260

    Google Scholar 

  10. Gupta S, Maheshwari A, Parab P et al (2018) Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 36(16):1548–1555

    Article  PubMed  CAS  Google Scholar 

  11. Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27(28):4649–4655

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III Trial JCOG0505. J Clin Oncol 33(19):2129–2135

    Article  PubMed  CAS  Google Scholar 

  13. Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6(Suppl 3):30–35

    Article  PubMed  CAS  Google Scholar 

  14. Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649

    Article  PubMed  CAS  Google Scholar 

  15. Bonilla L, Ben-Aharon I, Vidal L et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845–1854

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338

    Article  PubMed  CAS  Google Scholar 

  17. Mori T, Hosokawa K, Sawada M et al (2010) Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results. Int J Gynecol Cancer 20(4):611–616

    Article  PubMed  Google Scholar 

  18. Benedetti Panici P, Palaia I, Marchetti C et al (2015) Dose-dense neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer: a phase II study. Oncology 89(2):103–110

    Article  PubMed  CAS  Google Scholar 

  19. Vergote I, Debruyne P, Kridelka F et al (2015) Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: a study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecol Oncol 138(2):278–284

    Article  PubMed  CAS  Google Scholar 

  20. Zanaboni F, Grijuela B, Giudici S et al (2013) Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: results of a phase II multicentric study. Eur J Cancer 49(5):1065–1072

    Article  PubMed  CAS  Google Scholar 

  21. Salihi R, Leunen K, Moerman P et al (2017) Neoadjuvant weekly paclitaxel-carboplatin is effective in Stage I–II cervical cancer. Int J Gynecol Cancer 27(6):1256–1260

    Article  PubMed  Google Scholar 

  22. Tanioka M, Yamaguchi S, Shimada M et al (2017) Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. Med Oncol 34(8):134

    Article  PubMed  CAS  Google Scholar 

  23. Gadducci A, Barsotti C, Laliscia C et al (2017) Dose-dense paclitaxel- and carboplatin-based neoadjuvant chemotherapy followed by surgery or concurrent chemo-radiotherapy in cervical cancer: a preliminary analysis. Anticancer Res 37(3):1249–1255

    Article  PubMed  CAS  Google Scholar 

  24. Torfs S, Cadron I, Amant F et al (2012) Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer. Eur J Cancer 48(9):1332–1340

    Article  PubMed  CAS  Google Scholar 

  25. McCormack M, Kadalayil L, Hackshaw A et al (2013) A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 108(12):2464–2469

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. de Azevedo CRAS, Thuler LCS, de Mello MJG et al (2017) Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol 146(3):560–565

    Article  PubMed  CAS  Google Scholar 

  27. Ferrandina G, Palluzzi E, Gallotta V et al (2018) Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: a phase II study. Eur J Surg Oncol 44(7):1062–1068

    Article  PubMed  Google Scholar 

  28. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  29. Querleu D, Morrow CP (2009) Classification of radical hysterectomy. Gynecol Oncol 115(2):314–315

    Article  PubMed  Google Scholar 

  30. Chassagne D, Sismondi P, Horiot JC et al (1993) A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 26(3):195–202

    Article  PubMed  CAS  Google Scholar 

  31. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10

    Article  PubMed  CAS  Google Scholar 

  32. Kaplan FL, Meier P (1958) Non parametric estimation from incomplete observations. Am J Stat Assoc 53:457–481

    Article  Google Scholar 

  33. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170

    PubMed  CAS  Google Scholar 

  34. Clamp AR, McNeish I, Dean A et al (2017) ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Ann Oncol 28(suppl_5):v605–v649

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynecologic Oncology Unit, Department of Women and Children Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

    Gabriella Ferrandina, Giacomo Corrado, Valerio Gallotta, Eleonora Palluzzi, Mariagrazia Distefano & Giovanni Scambia

  2. Department of Obstetrics and Gynecology, Hospital “Paolo Giaccone”, Palermo, Italy

    Giuseppe Vitrano

Authors
  1. Gabriella Ferrandina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giacomo Corrado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Vitrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valerio Gallotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eleonora Palluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mariagrazia Distefano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanni Scambia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giacomo Corrado.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors are responsible for the content and writing of the paper.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 33 KB)

Supplementary material 2 (DOC 47 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferrandina, G., Corrado, G., Vitrano, G. et al. Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Cancer Chemother Pharmacol 83, 431–438 (2019). https://doi.org/10.1007/s00280-018-3742-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3742-1

Keywords

Search

Navigation